Status:
RECRUITING
Optimizing the Ocular Surface With Systane COMPLETE Pre- and Post-operatively in Patients With Dry Eye Planning for Cataract Surgery: An Extension Study of Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Ophthalmology
Eligibility:
All Genders
20-85 years
Phase:
PHASE4
Brief Summary
Compare the corneal astigmatism data before and after the use of Systane COMPLETE to evaluate its impact on predicting changes in postoperative residual astigmatism, as well as the effects of using or...
Detailed Description
STUDY OBJECTIVE： Compare the corneal astigmatism data before and after the use of Systane COMPLETE to evaluate its impact on predicting changes in postoperative residual astigmatism. Compare the effe...
Eligibility Criteria
Inclusion
- Inclusion Criteria (Experimental group ): Cataract patients who participated in the "Optimizing the Ocular Surface with Systane COMPLETE in Patients with Dry Eye Planning for Cataract Surgery" trial (Research Ethics Committee Approval Number: 202311109MIPD) and did not withdraw from the trial midway.
- Exclusion Criteria (Experimental group ): Patients unwilling to participate in this trial after surgery.
- Inclusion Criteria(Control group):
- Cataract patients aged between 20 and 85 years.
- Patients with normal cognitive function who are able to complete the dry eye questionnaire (with - responses recorded by the research team) and are willing to undergo phacoemulsification and intraocular lens implantation under topical anesthesia.
- Exclusion Criteria (Control group):
- Unable to answer the questions in the dry eye survey.
- Ocular trauma or ocular surgery in the planned surgical eye, active ocular infection, and obvious abnormalities in ocular surface or eyelid margins other than MGD cause decreased visual acuity other than cataracts.
- Dry eye signs: Corneal Fluorescein Staining CFS (+) to exclude any corneal abnormalities or epithelial defect.
- Systemic drug use, including tetracycline derivatives, antihistamines, and isotretinoin.
- Using dry eye medication at screening stage.
Exclusion
Key Trial Info
Start Date :
March 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT06886373
Start Date
March 25 2025
End Date
December 31 2027
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100